Theranostics · Literature Radar
I-131 thyroid-cancer ablation evidence — activity selection, recurrence imaging, hospital-discharge practice. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Zhu R, Wu Y, Lei YY, Luo ZX et al.
ObjectiveTo evaluate whether concomitant nodular goiter (NG) affects the short-term efficacy of radioactive iodine (RAI) therapy in postoperative differentiated thyroid carcinoma (DTC) patients.Method…
Shin J, Seo Y, Li Y, Diwanji D et al.
ObjectiveTo develop a patient-specific radiobiological dosimetry framework that incorporates tempora dose delivery and spatial heterogeneity using hybrid imaging for 131I therapy of metastatic thyroid…
Song H, Shen C, Fan Y, Liu Z et al.
BackgroundRadioiodine (RAI) alone exhibited limited efficacy in distant metastatic differentiated thyroid cancer (DTC). We hypothesized that pretreatment with anlotinib, a potent antiangiogenic tyrosi…
Chu J, Ma WH.
I-131 scintigraphy can be performed after I-131 radioactive iodine (RAI) treatment in appropriate patients for dynamic risk stratification. Sodium iodide symporter (NIS) expression is a mechanism resp…
McGoron AJ.
Differentiated thyroid cancer (DTC) is characterized by retention of thyroid-specific functions, particularly iodide uptake mediated by the sodium-iodide symporter (NIS), which underlies the effective…
Gloria MAV, Liamsuwan T, Cruzpero RCL, Magboo VPC et al.
PurposeAdult Filipinos are highly susceptible to differentiated thyroid carcinoma (DTC), which is managed with thyroidectomy followed by radioactive iodine (RAI) therapy. Currently, there is a lack of…
Huang Q, Huang G.
Background/Objectives: There is increasing interest in moving selected radiopharmaceutical therapy (RPT) applications toward treatment informed by patient-specific quantitative data. Patient-specific …
Athanassiou L, Athanassiou P, Kaiafa G, Savopoulos C et al.
Thyroid cancer is treated by a combination of surgical treatment in the form of thyroidectomy, administration of radioactive iodine and subsequent administration of thyroxine. The aim of radioactive i…
Kagodora SB, Baeyens A, Vral A, Di Tamba Willy Vangu M.
BackgroundThyroid cancer is the most common endocrine cancer globally. The National Cancer Registry has estimated the prevalence of the disease to be higher in females than in the male population with…
Sozio SJ, Cohen D, Raynor WY, Kempf JS.
PurposeIodine-131 (I-131) thyroid ablation is strictly contraindicated during pregnancy due to the risk of fetal thyroid damage after 10 weeks of gestation. Current society guidelines lack consistency…
Badawy M, McIntosh L, Jackson P, Jong I.
ObjectivePre-therapy blood-marrow dosimetry for ¹³¹I treatment of differentiated thyroid cancer (DTC) requires serial imaging and blood sampling, limiting clinical adoption. When blood data are unavai…
Heilfort P, Varlamova O, Kranick M, Bredow J et al.
AimPretherapeutic dosimetry is an essential component of individualized radioiodine therapy. This study aimed to compare radioiodine therapies planned according to the Marinelli equation or DIN 6861-1…
Luján-Expósito Á.
ObjectiveCurrent clinical practice guidelines often advocate for fixed [¹³¹I]NaI activity prescriptions based on patient diagnosis and risk stratification, frequently disregarding individual patient-s…
Tan G, Zhang Y, Mao Z, Zhang C et al.
BackgroundRadioiodine-refractory differentiated thyroid cancer (RAIR-DTC) poses a major therapeutic challenge, with loss of radioiodine avidity, limited treatment options, and worse outcomes. Current …
Liu T, Qiao J, Mao M, Guo Q et al.
BackgroundObservational studies report an overall-survival advantage for postoperative radioactive iodine (RAI) in lymph node-positive papillary thyroid carcinoma (PTC), but such estimates are vulnera…
Razak NA, Lee HMJ, Mathew A, Hassan SZA et al.
ObjectivesEmpirical fixed-activity radioiodine (RAI) therapy remains widely used in differentiated thyroid carcinoma (DTC), despite substantial inter-patient variability in iodine kinetics. Pre-therap…
Deng XZ, Liu MY, Shen CT, Song HJ et al.
BackgroundThe clinical utility of postoperative radioiodine (¹³¹I) ablation remains unclear for patients with initially diagnosed non-distant metastatic papillary thyroid carcinoma (PTC) with harborin…
Gao F, Zhang D, Luo Y, Li C.
Radioiodine (RAI) is a cornerstone of treatment for differentiated thyroid cancer (DTC), yet the immunological consequences of RAI-induced DNA damage remain poorly understood. Here, we examine cGAS-ST…
Lin SF, Lu YL, Wu CL, Chang SH et al.
ObjectiveTo investigate the association between radioactive iodine (RAI) treatment and the subsequent risk of second primary malignancies (SPMs) in thyroid cancer patients.DesignPopulation-based prope…
Chen L, Yu F, Zhao J, Luo Q et al.
ObjectivesRadioiodine-131 (¹³¹I) therapy is an important post-thyroidectomy treatment, but lesion diagnosis on post-therapy whole-body scans (RxWBS) is clinically challenging. This study aimed to prop…
Shi K, Zhang X, Huang S, Tian T et al.
BackgroundRET gene fusion is one of the key oncogenic drivers in papillary thyroid cancer (PTC). However, the impact of different RET fusion subtypes on clinicopathological features and radioiodine (R…
Hofmann MS, Kjems J, Zerahn B, Kristensen B et al.
The incidence of thyroid cancer has increased globally and in Denmark. Following total thyroidectomy, patients at intermediate or high risk undergo radioactive iodine (RAI) therapy with ¹³¹I to ablate…
Solakoğlu ME, Maman A, Laloğlu E.
Background/Objectives: Radioactive iodine (RAI) therapy is widely used after thyroidectomy for differentiated thyroid cancer, but early renal tubular changes may not be reflected by conventional renal…
Ezzati AO, Arasi M.
Iodine-131 is widely used in nuclear medicine, and accurate assessment of its internal dosimetry requires appropriate biokinetic and radiation transport models. Integrating physiological iodine kineti…
Hong CM, Gil J, Cheon GJ, Lee JH et al.
This study compared clinical and safety outcomes of radioactive iodine therapies administered after thyroid hormone withdrawal (THW) versus recombinant human thyrotropin (rhTSH) in patients with diffe…
Pacella S, Elisei F, Mattoli MV, Airò Farulla LS et al.
BackgroundPheochromocytomas and paragangliomas (PPGL) are rare and heterogeneous neuroendocrine tumors for which therapeutic options remain limited, particularly in the metastatic or progressive setti…
Shi Y, Huang J, Dong W, Lv C et al.
Most thyroid cancers are differentiated tumours with favourable outcomes, but a clinically important minority develops invasion, distant metastasis, loss of radioiodine uptake and histological dediffe…
Moritani S.
Since the introduction of sorafenib in 2014 and lenvatinib in 2015, multikinase inhibitors (MKIs) have substantially advanced systemic therapy for patients with radioactive iodine-refractory different…
Schroff A, Insulander Björk K, Rassol N, Johansson J et al.
BackgroundAssessing the biodistribution and absorbed dose of ¹³¹I is crucial for optimisation of radionuclide therapy, as well as for improving risk assessment following nuclear emergencies. After the…
Nieri A, Imperiale A, Urso L.
Ciappuccini R, Leman R, Castera L, Dorbeau M et al.
Fusion genes are the most common genetic alterations found in pediatric papillary thyroid cancers (PTCs). Pediatric PTCs harboring fusion genes are generally associated with more aggressive disease th…
Elston MS, Ranasinghe I, Meyer-Rochow GY, Tamatea JAU et al.
BackgroundFor solitary toxic adenoma (STA) hemithyroidectomy and radioactive iodine (RAI) both cure hyperthyroidism, but their hypothyroidism risks differ.AimTo review the thyroid status of patients w…
Zhu M, Hu T, Liu C, Li D et al.
Following nuclear accidents, Iodine-131 (131I) released as radioactive aerosols can be inhaled into the lungs, leading to radiation-induced pulmonary fibrosis (RIPF). Our previous studies have identif…
Lei Y, Mao Y, Zhu R, Luo Z et al.
BackgroundDifferentiated thyroid carcinoma (DTC) responses to initial post-operative I-131 therapy are heterogeneous. Standard binary models combine incomplete responses into a 'non-excellent' categor…
Ahmadi S, Hoseini M, Ravari MS, Zarei M et al.
The management of thyroid cancer has advanced through the integration of molecular imaging, genomic profiling, and bioinformatics, supporting precision oncology across diverse subtypes. Although radio…
Chan WL, Tin WW, Wong KC, Kwok CC et al.
Background: Lenvatinib is an established first-line therapy for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC); however, real-world data, particularly from Asian populations w…
Gu L, Zheng G, Zhao Y, Wang J et al.
BackgroundEarly post-treatment prognostic assessment may facilitate individualized follow-up in patients with differentiated thyroid cancer (DTC) after initial radioactive iodine (RAI) therapy (RAIT).…
Li YH, Wu J, Lee IT.
ContextPostsurgical radioactive iodine (RAI) therapy is indicated for adults with differentiated thyroid cancer (DTC) who are at an intermediate-to-high risk of recurrence. Thyrotropin (TSH) stimulati…
Suresh AR, Kung A, Chou J, Jonklaas J.
ContextVariability exists in the use of radioactive iodine (RAI) treatment in intermediate-risk (IR) thyroid cancer.ObjectiveThe study surveyed clinicians about their use of RAI in theoretical cases o…
Bagasariya R, Verma P, Basu S.
We report a case of follicular thyroid carcinoma presenting with a solitary skeletal metastasis in right iliac bone that remained structurally persistent after 2 high-dose 131I treatments. However, th…
Robson Chase ME, Hubbuch J, McMullen CA, Davenport D et al.
BackgroundThe decision to administer postoperative radioactive iodine therapy in differentiated thyroid cancer is evolving. Given the growing utility of large language models in medical decision-makin…
Asif M, Nisar M, Asif A, Batool M et al.
BackgroundRadioactive iodine (RAI) therapy is often administered post-total thyroidectomy in patients with low-risk differentiated thyroid carcinoma, despite guidelines advising against its routine ap…
Condello V, Strati M, Thor D, Larsson C et al.
Radioiodine therapy of differentiated thyroid cancer is effective and possibly curative in patients with metastatic lesions that retain iodine avidity. However, in clinical practice, iodine avidity in…
Li Y, He Z, Zhao M, Zhang B.
BackgroundStructural incomplete response (SIR) after radioactive iodine (RAI) therapy indicates persistent or recurrent structural disease and has important implications for the long-term management o…
Peterson ME, Carmody S, Rishniw M.
BackgroundLong-term thyroid status and survival after radioiodine treatment of hyperthyroid cats are incompletely characterized, particularly for cats developing iatrogenic hypothyroidism.Hypothesis/o…
Zhou L, Liu Y, Wu B, Meng X et al.
Radionuclide 131I is of vital importance in radiation protection and nuclear medicine. Its internal dose is mainly concentrated in the thyroid. The S value is a key parameter in the calculation of int…
Mintegui G, Martínez Z, Basantes M, Ferrando R.
IntroductionRadioiodine treatment in differentiated thyroid carcinoma requires elevated TSH levels to optimize the uptake of [131I]NaI. Levothyroxine suspension is the usual strategy for inducing endo…
Garcia-Regal C, Quiñones-Silva J, Brox-Torrecilla N, Martinez-Lorca A et al.
ObjectivePatients with differentiated thyroid carcinoma (DTC) classified as low risk of recurrence and an excellent response to initial treatment should have a particularly low risk of recurrence. Our…
Mallareddy Banala, Shabbir Ezuddin, Mark Foley, Russ Kuker
Artificial intelligence (AI) has been studied across radiopharmaceutical therapy (RPT); however, evidence for treatment-changing use remains limited. We conducted a structured narrative review with de…
Houssem Eddine Kamel, Makrem Tbini, Sarra Idriss, I. Riahi et al.
Purpose: Differentiated thyroid carcinoma (DTC) is the most common endocrine malignancy in children and adolescents. Pediatric DTC often presents with extensive nodal disease or pulmonary metastases, …
Rongfang Shen, Huiting Yang, Xiaoting Ye, Ziqing Li et al.
Background: In the current conventional recombinant human thyrotropin (rhTSH) protocol, radioiodine therapy (RAIT) is given at 24 h post-second injection and diagnostic 131 I whole-body scan (Dx-WBS) …
Pontes MLS, Verçosa AFA, Lima MCL, Assumpção LVM et al.
Rationale and objectivesDifferentiated thyroid carcinoma (DTC) has a favorable prognosis when properly managed. Whole-body scanning (WBS) is the standard functional imaging method for post-surgical st…
Yuqian Ren, Cuijuan Zheng, Meng Wang, Yanzhi Wang
Objective To investigate whether dynamic resolution of IL-6 and TNF-α after radioactive iodine (RAI) therapy is a key determinant of muscle recovery in Graves’ disease and to evaluate their potential …
Yang W, Ou M, Lu M, Wang BE et al.
PurposeThis study aimed to evaluate the knowledge, attitudes, and practices (KAP) regarding iodine-131 (I-131) therapy and their relationship with depression and anxiety in postoperative thyroid cance…
Mayurasakorn S, Somboonporn C, Theerakulpisut D.
Thyroglobulin (Tg) level is one of the well-known factors affecting the outcome of radioactive iodine treatment in differentiated thyroid cancer, though this tumor marker is affected by the thyroid-st…
Bello R, Yackobovitch-Gavan M, Lazar L, Hayek S.
BackgroundDifferentiated thyroid cancer (DTC) is the most common endocrine malignancy among children, adolescents, and young adults (CAYA). While prognosis is generally favorable, rising incidence, lo…
Wang J, Liu Z, Zhang Q, Sun W.
Thyroid cancer is the most common endocrine malignancy worldwide, with its incidence increasing markedly over the past several decades, while mortality trends have shown complex patterns. High‑risk re…
Sunny S, Hephzibah J.
Purpose of reviewThis review aims to compare the different methods of achieving adequate thyroid-stimulating hormone (TSH) stimulation prior to radioiodine (RAI) therapy in patients with differentiate…
Yerdes E, Okuyan M, Elboga U.
A 77-year-old man with papillary thyroid carcinoma had received radioactive iodine therapy for metastatic disease 8 years earlier and subsequently achieved remission. He represented with rising serum …
Showing the 60 most recent of 113 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
